A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

 
Web www.patentalert.com

< Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor

< Vitamin/mineral compositions with DHA

> Continuous process for production of oil seed protein isolate

> DRY EXTRACTS OF PELARGONIUM SIDOIDES AND PELARGONIUM RENIFORME

~ 00618